مورد إلكتروني
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year
| العنوان: | Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year |
|---|---|
| بيانات النشر: | TAYLOR & FRANCIS LTD 2022 |
| تفاصيل مُضافة: | Galluzzo, Marco Talamonti, Marina Bernardini, Nicoletta Chiricozzi, Andrea De Simone, Clara Bonifati, Claudio Bruni, Pierluigi Diotallevi, Federico Esposito, Maria Graceffa, Dario Hansel, Katharina Loconsole, Francesco Moretta, Gaia Mugheddu, Cristina Papini, Manuela Richetta, Antonio Skroza, Nevena Atzori, Laura Fargnoli, Maria Concetta Persechino, Severino Offidani, Annamaria Stingeni, Luca Peris, Ketty Potenza, Concetta Bianchi, Luca Chiricozzi, Andrea (ORCID:0000-0002-6739-0387) De Simone, Clara (ORCID:0000-0002-0898-0045) Peris, Ketty (ORCID:0000-0002-5237-0463) |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Background Real-world data on guselkumab, especially at times >6 months, are limited. Research design and methods We performed a longitudinal, retrospective analysis on 307 patients with moderate-severe chronic plaque psoriasis (Psoriasis Area Severity Index [PASI] >10) treated with guselkumab for up to 12 months. Main outcome measures PASI 75, PASI 90, and PASI 100 were assessed at baseline and at 4, 12, 20, 28, 36, 44, and 52 weeks. Results At 12 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 56.4%, 33.6%, and 24.1% of patients, respectively. At 52 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 82.7%, 68.7%, and 51.1% of patients, respectively. Patients without comorbidities and those naive to previous biological therapy had better responses. The mean Dermatology Life Quality Index score decreased from 14.0 at baseline to 3.1 at 12 weeks and 1.6 at 6 months, which was maintained at later times. Similar improvements were seen in pruritus visual analog scale. Conclusions Guselkumab maintains its efficacy for up to 12 months among responders in a real-world cohort of patients with moderate-severe plaque psoriasis, confirming data from prior real-world studies with smaller cohorts and shorter duration of follow-up. |
| مصطلحات الفهرس: | Guselkumab, efficacy, plaque psoriasis, real-world, treatment, Settore MED/35 - MALATTIE CUTANEE E VENEREE, info:eu-repo/semantics/article |
| URL: | info:eu-repo/semantics/altIdentifier/pmid/35708257 info:eu-repo/semantics/altIdentifier/wos/WOS:000815390400001 issue:N/A firstpage:1 lastpage:8 numberofpages:8 issueyear:2022 journal:EXPERT OPINION ON BIOLOGICAL THERAPY |
| الإتاحة: | Open access content. Open access content |
| ملاحظة: | English |
| أرقام أخرى: | SYC oai:publicatt.unicatt.it:10807/214086 10.1080/14712598.2022.2090835 info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85132841176 1355228199 |
| المصدر المساهم: | UNIV CATTOLICA DEL SACRO CUORE From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1355228199 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |